N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 3 ClinicalTrials.gov

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Sponsor: Regeneron Pharmaceuticals • ClinicalTrials.gov ID: NCT07410117

Registry updated: 2026-10-13
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Interventions

  • REGN7508 (Drug)
    Administered per the protocol
  • Placebo (Drug)
    Administered per the protocol

Eligibility criteria

Key Inclusion Criteria: 1. Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol 2. Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol 3. Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention Key Exclusion Criteria: 1. Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy) 2. Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma 3. Has a primary brain tumor or brain metastases as described in the protocol 4. Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period 5. Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Conditions

Cancer-Associated Thrombosis (CAT)

Locations

  • Bioresearch Partner- Hialeah Hospital — Hialeah, Florida, United States
  • Helios Clinical Research — North Miami Beach, Florida, United States
  • Memorial Sloan Kettering Cancer Center — New York, New York, United States
  • El Paso Medical Research Institute (Medresearch Inc) — El Paso, Texas, United States
  • LTD High Technology Hospital Medcenter — Batumi, Adjara, Georgia
  • Krystyna Kiel Oncology Center — Kutaisi, Imereti, Georgia
  • American Hospital Tbilisi — Tbilisi, Georgia
  • Llc Todua Clinic — Tbilisi, Georgia
  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic — Tbilisi, Georgia
  • Institute of Clinical Oncology — Tbilisi, Georgia
  • JSC Evex Hospitals - Caraps Medline — Tbilisi, Georgia
  • LTD Cancer Research Centre — Tbilisi, Georgia
  • Caucasus Medical Centre — Tbilisi, Georgia
  • Ehime University Hospital — Tōon, Ehime, Japan
  • Hyogo Cancer Center — Akashi, Hyōgo, Japan
  • Kagawa University Hospital — Kita-gun, Kagawa-ken, Japan
  • Tokai University Hospital — Isehara-Shi, Kanagawa, Japan
  • University Hospital Kyoto Prefectural University of Medicine — Kyoto, Kyoto, Japan
  • National Hospital Organization Osaka National Hospital (ONH) — Chuo, Osaka, Japan
  • Saitama Cancer Center — Ina-machi, Saitama, Japan
  • Tokyo Medical University Hospital — Shinjuku, Tokyo, Japan
  • Yamaguchi University Hospital — Ube, Yamaguchi, Japan
  • Niigata University Medical & Dental Hospital — Niigata, Japan
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record